Subjective response to lysine in the therapy of herpes simplex.
To test the effect of lysine supplementation on herpes infection, 1543 subjects were surveyed by questionnaire after a six-month trial period. The study included subjects with cold sores, canker sores, and genital herpes. Of these, 54% had been diagnosed and treated by a physician. The results showed that the average dosage used was 936 mg of lysine daily. Eighty-four per cent of those surveyed said that lysine supplementation prevented recurrence or decreased the frequency of herpes infection. Whereas 79% described their symptoms as severe or intolerable without lysine, only 8% used these terms when taking lysine. Without lysine, 90% indicated that healing took six to 15 days, but with lysine 83% stated that lesions healed in five days or less. Overall, 88% considered supplemental lysine an effective form of treatment for herpes infection.
D000998:Antiviral Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy; D006560:Herpes Labialis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy*; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D008239:Lysine / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D013283:Stomatitis, Herpetic / Q000188:drug therapy
D000998:Antiviral Agents; D008239:Lysine